Business
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting NANTES, France – September 22, 2025, 8:00 a.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that two international proxy advisory firms, including Glass Lewis, recommend shareholders to vote IN FAVOR of the resolutions proposed by the Board of Directors regarding its composition (resolutions 5 to 8) at the general meeting of
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting","length":143,"tagName":"p"},{"type":"text","content":"NANTES, France – September 22, 2025, 8:00 a.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that two international proxy advisory firms, including Glass Lewis, recommend shareholders to vote IN FAVOR of the resolutions proposed by the Board of Directors regarding its composition (resolutions 5 to 8) at the general meeting of shareholders on September 30, 2025 (the “General Meeting”).","length":416,"tagName":"p"},{"type":"text","content":"Glass Lewis also recommends voting AGAINST all resolutions proposed by the group of minority shareholders acting in concert (resolutions A to K) and specifies in this regard:","length":174,"tagName":"p"},{"type":"text","content":"“We do not believe that [the group of minority shareholders acting in concert] have presented a compelling alternative which results in a clearly superior alternative to the Company’s current strategic approach. While we remain open to constructive dialogue, we believe that management’s current strategy warrants additional time to fully develop and demonstrate its long-term potential. Moreover, we recognize the management’s efforts to incorporate members of the dissident group onto the board, reflecting a commitment to balanced representation and inclusive governance.”1","length":576,"tagName":"p"},{"type":"text","content":"The other firm, highlighting that the Company’s current governance practices and management do not appear to be detrimental to the Company’s performance, also recommends OSE’s shareholders to reject the majority of dissenting resolutions, in particular resolutions “B,” “C,” “E,” “F,” “G,” “H,” “J,” an...